Zero to Hero? Scope 3 Emissions – A Strategic Imperative for Pharma Companies Verena Ahnert Read more
Published Articles Life Sciences & Pharma Investing in Psychedelic Therapies: Market Challenges and Opportunities December 23, 2025
Executive Insights Life Sciences & Pharma Unlocking Brazil’s Clinical Trial Opportunity: A Strategic Roadmap for Healthcare Leaders August 18, 2025
Executive Insights Life Sciences & Pharma When Is It Too Late? Drivers of Commercial Performance for Late Entrants in Biopharma April 28, 2025
Executive Insights Life Sciences & Pharma Transitioning to EU-Wide Health Technology Assessments: Implications for Pharma April 14, 2025
Case Study Life Sciences & Pharma Optimizing Four-Wall DC Operations for a Pharmaceutical Distributor March 27, 2025 After years of stable but stagnant warehouse performance, a major pharmaceutical distributor sought to modernize its technology infrastructure to boost…
Executive Insights Life Sciences & Pharma Aligning Aseptic Fill/Finish Operations With Global Pharmaceutical Demand February 3, 2025
